Clinical Trial

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Protocol Amendment History 5 changes
notable Trial sites expanded: 29 -> 34 locations 2026-07-28
notable Trial sites expanded: 25 -> 29 locations 2026-06-09
notable Trial sites expanded: 12 -> 25 locations 2026-04-23
notable Primary completion pushed: 2027-07 -> 2028-12-31 2026-04-23
minor Completion pushed: 2028-07 -> 2029-06 2026-04-23
Trial Details
NCT Number NCT06989359
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN
Enrollment 45 participants
Start Date 2025-08-28
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-27